IP Library › Patent Application 14347602
Patent Application
App. No. 14/347,602

Treatment of Obesity and Obesity-Related Disorders by Pharmalogical Targeting of Kv 1.3 Potassium Channels

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/347,602
Abstract

Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.

Claims (25)

1 - 48 . (canceled)

49 . A method for activation of brown adipose tissue, treating obesity or treating an obesity-related disorder in a human or animal subject, said method comprising the steps of administering to the subject an agent which inhibits potassium channels.

50 . A method according to claim 49 wherein the agent comprises the ShK toxin (SEQ ID NO:1)

51 . A method according to claim 49 wherein the agent comprises a modified ShK toxin selected from: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7.

52 . A method according to claim 49 wherein the agent comprises an ShK toxin attached to a chemical entity.

53 . A method according to claim 52 wherein the chemical entity attached to ShK toxin is selected from: AEEAc-L-Tyr(PO 3 H 2 ), AEEAc-L-Pmp(OH 2 ), AEEAc-D-Pmp(OH 2 ), AEEAc-D-Pmp(OH, Et), AEEAc-L-Pmp(Et 2 ), AEEAc-D-Pmp(Et 2 ), AEEAc-L-Tyr, AEEAc-L-Phe(p-NH 2 ), AEEAc-L-Phe(p-CO 2 H), AEEAc-L-Aspartate, AEEAc-D-Aspartate, AEEAc-L-Glutamate, or AEEAc-D-Glutamate

54 . A method according to claim 49 wherein said chemical entity is attached to the N-terminal residue of ShK.

55 . A method according to claim 49 wherein the ShK toxin is obtained from a natural source.

56 . A method according to claim 49 wherein the ShK toxin is synthetic.

57 . A method according to claim 52 wherein the chemical entity includes a fluorophore tag.

58 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-L-Pmp(OH 2 ).

59 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-D-Pmp(OH 2 ).

60 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-D-Pmp(OH, Et).

61 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-L-Pmp(Et 2 ).

62 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-D-Pmp(Et 2 ).

63 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-L-Tyr.

64 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-L-Phe(p-NH 2 ).

65 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-L-Phe(p-CO 2 H).

66 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-L-Aspartate.

67 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-D-Aspartate.

68 . A method according to claim 52 wherein the chemical entity attached to ShK toxin comprises AEEAc-L-Glutamate.

69 . A method according to claim 52 wherein the chemical entity attached to ShK toxin AEEAc-D-Glutamate.

70 . A method according to claim 49 wherein the agent inhibits Kv1.3 potassium channels.

71 . A method according to claim 49 wherein the agent selectively inhibits Kv1.3 more than Kv1.1 potassium channels.

72 . A method according to claim 49 wherein the chemical entity attached to ShK toxin further comprises proteins in-frame or polyethylene glycols of differing sizes.